Mineralys Therapeutics (MLYS) Shares Outstanding (2022 - 2026)

Mineralys Therapeutics has disclosed Shares Outstanding across 5 years of filings, most recently posting $82.5 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $82.5 million, up 27.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $82.5 million (up 27.1% YoY), and the FY2025 annual result was $81.5 million, up 63.66% from the prior year.
• Shares Outstanding came in at $82.5 million for Q1 2026 at Mineralys Therapeutics, up from $81.5 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $82.5 million in Q1 2026 to a low of $5.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $49.6 million (2024), against an average of $44.7 million.
• Across the five-year window, Shares Outstanding jumped 627.71% in 2023 and increased 21.05% in 2024, its largest moves.
• Mineralys Therapeutics' Shares Outstanding stood at $6.4 million in 2022, then soared by 540.79% to $41.1 million in 2023, then grew by 21.12% to $49.8 million in 2024, then jumped by 63.66% to $81.5 million in 2025, then increased by 1.13% to $82.5 million in 2026.
• The last three Shares Outstanding figures came in at $82.5 million (Q1 2026), $81.5 million (Q4 2025), and $79.0 million (Q3 2025), per Business Quant data.